Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection

Audio By Carbonatix

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 13, 2025--

Nexus Pharmaceuticals, LLC announces the U.S Food and Drug Administration (FDA) approval of Tacrolimus Injection 5 mg/mL. Nexus’ Tacrolimus Injection is the first and only vial that will be available.

“We are pleased to share the FDA approval of Tacrolimus Injection. Tacrolimus is a critical treatment option for patients requiring immunosuppressive therapy, enhancing their quality of life, and reducing the risk of organ rejection,” says Usman Ahmed, Chief Executive Officer at Nexus Pharmaceuticals, LLC. “We are proud to provide another reliable and effective treatment that supports successful patient outcomes and overall healthcare efficiency.”

Tacrolimus Injection 5 mg/mL (Single-Dose Vial) in a 10-pack will be launching soon.

About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they’re needed most.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250213151146/en/

CONTACT: Grace Conroy

[email protected]

847-527-7490

KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH FDA OTHER HEALTH

SOURCE: Nexus Pharmaceuticals, LLC

Copyright Business Wire 2025.

PUB: 02/13/2025 02:15 PM/DISC: 02/13/2025 02:17 PM

http://www.businesswire.com/news/home/20250213151146/en